Old Web
English
Sign In
Acemap
>
authorDetail
>
Hayato Yokota
Hayato Yokota
Akita University
Lung cancer
Medicine
Gefitinib
Pharmacology
Pharmacokinetics
4
Papers
11
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
2021
Biology
Hayato Yokota
Kazuhiro Sato
Sho Sakamoto
Yuji Okuda
Mariko Asano
Masahide Takeda
Katsutoshi Nakayama
Masatomo Miura
Show All
Source
Cite
Save
Citations (0)
ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
2020
Investigational New Drugs
Sho Sakamoto
Kazuhiro Sato
Yuri Takita
Yuka Izumiya
Naho Kumagai
Kazuhisa Sudo
Yukiyasu Hasegawa
Hayato Yokota
Yumiko Akamine
Yuji Okuda
Mariko Asano
Masahide Takeda
Masaaki Sano
Masatomo Miura
Katsutoshi Nakayama
Show All
Source
Cite
Save
Citations (1)
Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer.
2020
Journal of Clinical Pharmacy and Therapeutics
Hayato Yokota
Kazuhiro Sato
Sho Sakamoto
Yuji Okuda
Mariko Asano
Masahide Takeda
Katsutoshi Nakayama
Masatomo Miura
Show All
Source
Cite
Save
Citations (0)
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non–small-cell Lung Cancer
2017
Clinical Lung Cancer
Hayato Yokota
Kazuhiro Sato
Yuji Okuda
Hiroyuki Kobayashi
Masahide Takeda
Mariko Asano
Hiroshi Ito
Masatomo Miura
Show All
Source
Cite
Save
Citations (10)
1